Skip to main content
. Author manuscript; available in PMC: 2018 Dec 15.
Published in final edited form as: Cancer Res. 2017 Oct 16;77(24):6950–6962. doi: 10.1158/0008-5472.CAN-17-0981

Figure 4. Loss of myristoylation in Src kinase inhibits the synergy of Src(WT) with androgen receptor (AR) in prostate tumorigenesis.

Figure 4

(A) Schematic for examining the synergy of Src and AR in prostate tumorigenesis. Primary prostate epithelial cells were transduced with AR (GFP marker), Src(WT) (RFP marker), Src(G2A) (RFP marker), or co-transduced with Src(WT)/Src(G2A) and AR and the infected cells were combined with UGSM, and implanted under the renal capsule of SCID mice. Regenerated prostate tissue was isolated after 8 weeks. (B) Representative images of regenerated prostate tissue and RFP/GFP detection (scale bar, 2 mm). The weight of prostate tissues was compared in the bar graph. The * indicates an unpaired, two-tailed t test. (C) H&E, RFP/GFP, and IHC staining of AR and total Src, and co-staining of CK8, CK5 and DAPI in regenerated tissue. Scale bar, 100 µm.